SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
ARIAD Pharmaceuticals
An SI Board Since September 1996
Posts SubjectMarks Bans Symbol
4474 134 0 ARIA
Emcee:  jaybe Type:  Moderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
4374merriam-webster.comtktom-8/17/2016
4373Gotta be a legal term. Thanks Scottyosarian_2-8/17/2016
4372Fungible is not a typo. CMO = Contract Manufacturing Organization.DewDiligence_on_SI-8/17/2016
4371CMO's? Certified manufacturing operations? Fungibles, do they have a fungus?yosarian_2-8/17/2016
4370As Peter said, there are a lot of CMOs. Many of them are fungible.DewDiligence_on_SI-8/17/2016
4369Any ideas who these third party companies are? California gold rush, the people yosarian_2-8/17/2016
4368>>Assume there are probably companies that specialize in manufacture Yes,Biomaven-8/17/2016
4367From the most recent 10-K (page 12): sec.gov Iclusig, brigatinib, AP32788 and DewDiligence_on_SI-8/17/2016
4366Peter, Different subject but I'm curious. How does Ariad manufacture their dyosarian_2-8/17/2016
4365Although there is lots of talk on the IHUB Message Board re a Short Squeeze whiccivic08801-8/13/2016
4364>>"virgin" patient This was my very non-standard terminology. IBiomaven-8/9/2016
4363Jaybe, supposing many new virgin patients are prescribed Brigatinib (off label) tktom-8/8/2016
4362Lost soul.....tktom-8/8/2016
4361Amen. Same old post for years. Maybe $30 in a fantasy world.testad-8/8/2016
4360Broken record (eom).DewDiligence_on_SI-8/8/2016
4359ARIA will go from $10 to $15 a share in the next three months,with a $30 B/O by civic08801-8/8/2016
4358Moffit Center in Tampa finds preclinical superiority for pona in RET+ NSCLC... jaybe-8/5/2016
4357Jaybe, this will have a profound effect(decrease) on off label use for 1st line jesspro-8/5/2016
4356Looks like beginning of end of $3.6B frontline market in CML... Surprising to sjaybe-8/5/2016
4355Thank you gentlemen...jesspro-8/4/2016
4354The appeal resulted in ALTA-1L, a potential frontline approval on only 270 patiejaybe-8/3/2016
4353>>s that not enough as a bargaining tool for the company to appeal for a 1Biomaven-8/3/2016
4352Jaybe, supposing many new virgin patients are prescribed Brigatinib (off label) jesspro-8/3/2016
4351ALTA-1L allows one line of prior chemo, ALEX (alectinib) trial was treatment-naijaybe-8/3/2016
4350Do you mean when Crizotinib maker conducted the clinical trials, the patients hajesspro-8/3/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News